These findings indicate that ApoE4 disrupts insulin signaling and enhances GSK‐3β activity in T2DM mice, which can contribute to the exacerbated AD‐related pathology in ApoE4‐T2DM populations. This evidence concerns the gene APOE and type 2 diabetes mellitus.